NCT06755775 PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
| NCT ID | NCT06755775 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Diffuse Large B-Cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-07-23 |
| Primary Completion | 2029-07-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2024-07-23 with a primary completion date of 2029-07-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.
Eligibility Criteria
Inclusion Criteria: 1. Pathologic diagnosis of DLBCL 2. Patient's general condition is good and survival is expected to be greater than six months 3. Signed and dated informed consent form Exclusion Criteria: 1. Combined with other malignant tumors 2. Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study 3. Pregnant women and women at risk of pregnancy, breastfeeding women 4. poor compliant
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06755775 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diffuse Large B-Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06755775 currently recruiting?
Yes, NCT06755775 is actively recruiting participants. Contact the research team at zxy16zz@163.com for enrollment information.
Where is the NCT06755775 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06755775 clinical trial?
NCT06755775 is sponsored by Ruijin Hospital. The trial plans to enroll 150 participants.